Logo image
RNA-encapsulating lipid nanoparticles in cancer immunotherapy: From pre-clinical studies to clinical trials
期刊文章   同儕審查

RNA-encapsulating lipid nanoparticles in cancer immunotherapy: From pre-clinical studies to clinical trials

Tiffaney HsiaYunching Chen
European Journal of Pharmaceutics and Biopharmaceutics, 卷.197, 114234
04/2024
PMID: 38401743

摘要

Biotechnology Pharmaceutical Science
Nanoparticle-based delivery systems such as RNA-encapsulating lipid nanoparticles (RNA LNPs) have dramatically advanced in function and capacity over the last few decades. RNA LNPs boast of a diverse array of external and core configurations that enhance targeted delivery and prolong circulatory retention, advancing therapeutic outcomes. Particularly within the realm of cancer immunotherapies, RNA LNPs are increasingly gaining prominence. Pre-clinical in vitro and in vivo studies have laid a robust foundation for new and ongoing clinical trials that are actively enrolling patients for RNA LNP cancer immunotherapy. This review explores RNA LNPs, starting from their core composition to their external membrane formulation, set against a backdrop of recent clinical breakthroughs. We further elucidate the LNP delivery avenues, broach the prevailing challenges, and contemplate the future perspectives of RNA LNP-mediated immunotherapy.

相關連結

指標

1 檢視次數

詳細資料

Logo image